Evidence map›Paper›PMID 30647436›Full record

Trial reportEuropean journal of clinical nutrition2019

A pilot study of the effect of phospholipid curcumin on serum metabolomic profile in patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial.

Saeed Chashmniam, Seyed Reza Mirhafez, Maryam Dehabeh, Mitra Hariri, Mohsen Azimi Nezhad, B Fatemeh Nobakht M Gh

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European journal of clinical nutrition, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 6 pooled it
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 6 syntheses or guidelines pooled it, 92 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Review
  10. Review
  11. Review
  12. Clinical Potential ofFoods (Basel, Switzerland) · 2025
    Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Saeed ChashmniamDepartment of Chemistry, Sharif University of Technology, Tehran, Iran.
Seyed Reza MirhafezDepartment of Basic Medical Sciences, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Maryam DehabehDepartment of Biology, Payamnoor University, Mashhad, Iran.
Mitra HaririDepartment of Basic Medical Sciences, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Mohsen Azimi NezhadDepartment of Basic Medical Sciences, Neyshabur University of Medical Sciences, Neyshabur, Iran.
B Fatemeh Nobakht M GhDepartment of Basic Medical Sciences, Neyshabur University of Medical Sciences, Neyshabur, Iran. nobakhtf1@nums.ac.ir.ORCID http://orcid.org/0000-0002-2500-0002
University of Neyshabur · IRPayame Noor University · IRSharif University of Technology · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesCurcumin, a natural polyphenol compound in the spice turmeric, has been found to have potent anti-oxidative and anti-inflammatory activity. Curcumin may treat non-alcoholic fatty liver disease (NAFLD) through its beneficial effects on biomarkers of oxidative stress (OS) and inflammation, which are considered as two feature of this disease. However, the effects of curcumin on NAFLD have been remained poorly understood. This investigation evaluated the effects of administrating curcumin on metabolic status in NAFLD patients. SUBJECTS/

methodsFifty-eight NAFLD patients participated in a randomized, double-blind, placebo-controlled parallel design of study. The subjects were allocated randomly into two groups, which either received 250 mg phospholipid curcumin or placebo, one capsule per day for a period of 8 weeks. Fasting blood samples were taken from each subject at the start and end of the study period. Subsequently, metabolomics analysis was performed for serum samples using NMR.

resultsCompared with the placebo, supplementing phospholipid curcumin resulted in significant decreases in serum including 3- methyl-2-oxovaleric acid, 3-hydroxyisobutyrate, kynurenine, succinate, citrate, α-ketoglutarate, methylamine, trimethylamine, hippurate, indoxyl sulfate, chenodeoxycholic acid, taurocholic acid, and lithocholic acid. This profile of metabolic biomarkers could distinguish effectively NAFLD subjects who were treated with curcumin and placebo groups, achieving value of 0.99 for an area under receiver operating characteristic curve (AUC).

conclusionsCharacterizing the serum metabolic profile of the patients with NAFLD at the end of the intervention using NMR-based metabolomics method indicated that the targets of curcumin treatment included some amino acids, TCA cycle, bile acids, and gut microbiota.

Indexed as

MetabolomicsAdultAnti-Inflammatory AgentsAntioxidantsBiomarkersCurcuminDietary SupplementsDouble-Blind MethodFemaleHumansIranMagnetic Resonance SpectroscopyMaleMiddle AgedNon-alcoholic Fatty Liver DiseasePilot ProjectsAnti-Inflammatory AgentsAntioxidantsBiomarkersCurcuminPlacebos

Identifiers

PMID30647436
OpenAlexW2910110268

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.